CN106074366A - Injection of disturbance of consciousness and preparation method thereof after treatment cerebral trauma and brain surgery - Google Patents
Injection of disturbance of consciousness and preparation method thereof after treatment cerebral trauma and brain surgery Download PDFInfo
- Publication number
- CN106074366A CN106074366A CN201610430919.3A CN201610430919A CN106074366A CN 106074366 A CN106074366 A CN 106074366A CN 201610430919 A CN201610430919 A CN 201610430919A CN 106074366 A CN106074366 A CN 106074366A
- Authority
- CN
- China
- Prior art keywords
- injection
- disturbance
- consciousness
- stirring
- edaravone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to pharmaceutical technology field, it is specifically related to a kind of treat injection of disturbance of consciousness and preparation method thereof after cerebral trauma and brain surgery, is mainly made up of active component Edaravone, sodium chloride, cysteine hydrochloride, disodium glycyrrhizinate, methyl hydroxybenzoate, pH adjusting agent and water for injection.The foamless generation of preparation prepared by the present invention, avoid the foam adhesion at ampoule bottleneck, effectively solve during high temperature sealing by fusing owing to medicinal liquid carbonization causes the generation of the defective phenomenon of visible foreign matters, furthermore invention formulation steady quality, technique is simple, investigates indices through long-term experiment and all meets regulation.
Description
Technical field
The invention belongs to pharmaceutical technology field, be specifically related to a kind of treat the injection of disturbance of consciousness after cerebral trauma and brain surgery
Liquid and preparation method thereof.
Background technology
Trauma Brain Infarct Were Analyzed (traumatic cerebral infarction TCI) is more serious concurrent of craniocerebral injury
One of disease, the particularly generation of large area infraction will increase the weight of the infringement of brain function, have a strong impact on the prognosis of patient.And for cranium brain
The patient of damage, because disturbance of consciousness is serious, the symptom of primary lesion masks the sings and symptoms of cerebral infarction so that TCI's
Early discovery is extremely difficult.Craniocerebral injury cerebral Infarction often hides morbidity, rapid progress, is easily covered by the symptom of primary wound, special
It not that comatose patient is less susceptible to find, easily delay treatment.
The formation mechenism of Trauma Brain Infarct Were Analyzed mainly have several lower some:
1. disturbances of blood coagulation
Cerebral tissue is destroyed, and thromboplastin discharges in a large number, and blood brain barrier goes to pot, and activates extrinsic coagulation system, produces
Sick rationality thrombin, finally causes the thrombosis in cerebrovascular.
2. hemodynamic responses
Cranium pressure height, widely applies dehydrant, causes pachyemia, and blood viscosity raises.Massive blood loss, shock in operation are drawn
Playing intracranial Low perfusion, blood viscosity slows down with blood flow and significantly raises, and causes the thrombosis of intracranial vessel.When patient is the highest
When blood pressure, coronary heart disease, diabetes, it is more easy to the complication that cerebral infarction occurs.
3. blood supply district blood vessel injury
Operative site deeply tumor, Gigantic Meningioma, often easy damaged is adjacent in cerebrovascular malformation art blood vessel；Postoperative cerebral
Edema, increased intracranial pressure cause cerebrovascular distortion, elongate and spasm；Because operation wound causes the stress of body, cause complete
Body arteriolospasm, circulatory disturbance, induce thrombosis.
Edaravone is that first Mitsubishi Tokyo drugmaker develops, and April 4 calendar year 2001 is worked by medical treatment in Japan
Department of Welfare's approval Clinical practice, this medicine is aqueous injection in Japan's listing dosage form, and specification is 30mg/20ml, and adjuvant is bisulfite
Sodium and cysteine hydrochloride, usual using dosage is each 30mg, every day 2 times, is dissolved in normal saline or other diluents quiet
Arteries and veins instils, and uses no more than the most continuously 14 days, for improving the various Spirit nerve symptoms of diseases of acute period of cerebral infarction and various machine
Can obstacle.
Edaravone (Edaravone) is the one in pyrazolone derivative, its chemical entitled 3-methyl isophthalic acid-phenyl-
2-pyrazoles woods-5-ketone, molecular formula C10H10N2O, chemical structural formula is as follows:
Edaravone Injection easily aoxidizes during storage, and it has related substance to increase, and content declines.Antioxygen
Agent sodium sulfite, cysteine hydrochloride can increase the stability of Edaravone, in order to prevent active component Edaravone quilt
Oxidation, all adds the antioxidant such as sodium sulfite, cysteine hydrochloride in commercial preparation, its prescription is as follows
Easily aoxidizing during storage based on Edaravone Injection, it has related substance to increase, under its content
Fall.Current patent has carried out research and inquirement primarily with respect to problem above.
Such as: Chinese Patent Application No.: 03116418.8 discloses the pharmaceutical composition of a kind of cerebral protective agent, its main medicine
Reason active component is Edaravone.The preparation method of this pharmaceutical composition is by Edaravone and the different alkali pharmaceutically allowed
Property material is prepared, and makes clear solution, then according to lyophilizing technique carries out lyophilization, makes Edaravone freeze-dried powder
Agent.
Chinese Patent Application No.: 201010022006.0 disclose a kind of injection containing Edaravone, the present invention's
Containing the high concentration injection of Edaravone, by 1～the Edaravone of 5% (w/v), 5～the 1,2-PD of 25% (v/v), 5
～the ethanol of 15% (v/v) and water for injection form, pH value is 4.5～5.5.The Edaravone Injection of the present invention makes in clinic
Used time, add in sodium chloride transfusion to patient's intravenous drip, add the patient population being suitable for use, be suitable to more acute cerebral infarction
Patient uses.
Chinese Patent Application No.: 201010216022.3 disclose the Edaravone Injection of a kind of stable safety, this note
Penetrate liquid Edaravone Injection, comprise Edaravone and pharmaceutically acceptable adjuvant, it is characterised in that this injection contains phosphorus
Acid, L-cysteine hydrochloride and the antioxidant of sodium sulfite composition and pH adjusting agent.Joining at Edaravone Injection
After using omnidistance nitrogen charging deoxygenation method and sterilizing in system and potting process, rapid cooling method, improves stablizing of Edaravone Injection
Property, substantially reduce related substance-dimeric content, provide stable safe Edaravone Injection for clinical application.
Chinese Patent Application No.: 201110086709.4 disclose a kind of pharmaceutical composition containing edaravone compound and
Its preparation method, this pharmaceutical composition is by Edaravone, L-cysteine hydrochloride, anhydrous sodium sulfite, sodium chloride and injection
Form with water.The pharmaceutical composition stable in properties containing edaravone compound that the present invention provides.
Chinese Patent Application No.: 201310035122.X disclose a kind of Edaravone Injection being not added with antioxidant and
Preparation method.It is an object of the invention to provide a kind of impurity few, the preparation time is short, without adding the Edaravone injection of antioxidant
Liquid, it contains following component: Edaravone, pH value regulator, water for injection；Preparation method step is: A, dosing；B, filtration；
C, fill；D, sterilizing；Inflated with nitrogen protection in front 3 steps, and strictly control remaining oxygen and product impurity content in water, it is ensured that
Its safe and effective at Clinical practice.
Chinese Patent Application No.: 201310299714.2 disclose a kind of Edaravone Injection and preparation method thereof, institute
Containing vitamin C and glutathion in the Edaravone Injection stated, in described Edaravone Injection, Edaravone dense
Degree is 0.1%-0.2% (W/V), and ascorbic concentration is 0.1%-0.5% (W/V), and the concentration of glutathion is 1.0%-
10.0% (W/V).The present invention has the advantages that compared to existing technology: the present invention is by Edaravone, vitamin C, paddy
The rational proportion of the sweet peptide of Guang, makes three's synergism, plays its good anti-oxidation characteristics, has good to brain injury and complication thereof
Good therapeutical effect, and stability is high.
But inventor inventor in actual production finds, in the pouring process of medicinal liquid, medicinal liquid can produce substantial amounts of
Bubble, bubble hangs over and can not eliminate in time on filling pin, thus adhered to bottleneck, and Edaravone Injection uses ampoule bottle to fill
Dress, can cause the medicinal liquid carbonization of adhesion during high temperature sealing by fusing, cause the underproof situation of visible foreign matters to occur.
Summary of the invention
For above not enough, the invention provides a kind of injection treating disturbance of consciousness after cerebral trauma and brain surgery and
Preparation method, inventor finds that in actual test disodium glycyrrhizinate has the effect of its oxidation of suppression equally to Edaravone
Really, simultaneously under disodium glycyrrhizinate and methyl hydroxybenzoate synergism it can be avoided that Edaravone Injection occurs bubble in process of production
Foam, the injection that therefore present invention provides is mainly by active component Edaravone, sodium chloride, cysteine hydrochloride, glycyrrhizic acid two
Sodium, methyl hydroxybenzoate, pH adjusting agent and water for injection composition.
The injection that the present invention provides: described active component Edaravone concentration is 1.0～4.0mg/ml.
The present invention provide injection: described sodium chloride is isoosmotic adjusting agent, the addition of its quantity with injection for etc.
Ooze and add foundation for it.
The injection that the present invention provides: described CYSTEAMINE HCL acid concentration is 0.2～0.4mg/ml.
The injection that the present invention provides: described disodium glycyrrhizinate concentration is 0.8～1.2mg/ml.
The injection that the present invention provides: described methyl hydroxybenzoate concentration is 0.1～0.3mg/ml.
The injection that the present invention provides:, described active component Edaravone concentration is 1.5mg/ml, described hydrochloric acid half
Cystine concentration is 0.3mg/ml, and described disodium glycyrrhizinate concentration is 1.0mg/ml, and described methyl hydroxybenzoate concentration is
0.2mg/ml。
The injection that the present invention provides: described pH adjusting agent is in sodium hydroxide, sodium phosphate, sodium acetate and sodium citrate
One or several, pH scope is 4.6～5.2.
The injection that the present invention provides: described injection is sodium hydroxide, and pH is 4.9.
Invention further provides and a kind of treat the preparation method of the injection of disturbance of consciousness after cerebral trauma and brain surgery,
Mainly comprise the steps that and weigh the cysteine hydrochloride of recipe quantity and disodium glycyrrhizinate is dissolved in the water for injection of 70～90%
In, stirring and dissolving, add the Edaravone of recipe quantity, stirring and dissolving, regulate pH value by pH value regulator, pH value regulation is complete,
Adding methyl hydroxybenzoate and the sodium chloride of recipe quantity, stirring and dissolving, again regulate pH value by pH value regulator, pH value regulation is complete,
Being settled to total amount, stirring and evenly mixing with water for injection, filter, fill, sterilizing, visual inspection gets product.
The preparation method of the injection that the present invention provides, more preferably following steps: weigh the hydrochloric acid half of recipe quantity
Cystine and disodium glycyrrhizinate are dissolved in the water for injection of 80%, stirring and dissolving, add the Edaravone of recipe quantity, stir molten
Solving, regulate pH value with the sodium hydroxide solution of 0.1mol/L, pH value regulation is complete, adds methyl hydroxybenzoate and the chlorination of recipe quantity
Sodium, stirring and dissolving, again with the sodium hydroxide solution regulation pH value of 0.1mol/L, pH value regulation is complete, uses water for injection constant volume
To total amount, stirring and evenly mixing, filtering, fill, sterilizing, visual inspection gets product.
Above-mentioned injection of the present invention compared with prior art has the advantage that preparation prepared by the present invention is still
The generation of foam, it is to avoid the foam adhesion at ampoule bottleneck, effectively solves during high temperature sealing by fusing owing to medicinal liquid carbonization is led
Causing the generation of the defective phenomenon of visible foreign matters, furthermore invention formulation steady quality, technique is simple, investigates every through long-term experiment
Index all meets regulation.
Detailed description of the invention
Embodiment 1:
Prescription
Preparation technology
The cysteine hydrochloride and the disodium glycyrrhizinate that weigh recipe quantity are dissolved in appropriate water for injection, and stirring and dissolving adds
Enter the Edaravone of recipe quantity, stirring and dissolving, regulate pH value by pH value regulator, add methyl hydroxybenzoate and the chlorination of recipe quantity
Sodium, stirring and dissolving, again regulate pH value by pH value regulator, pH value regulation is complete, is settled to total amount with water for injection, and stirring is mixed
Even, to filter, fill, sterilizing, visual inspection gets product.
Embodiment 2:
Prescription
Preparation technology: with embodiment 1
Embodiment 3:
Prescription
Preparation technology: with embodiment 1
Embodiment 4
Prescription
Preparation technology: with embodiment 1
Embodiment 5
Prescription
Preparation technology: with embodiment 1
Comparative example 1:
Prescription
Preparation technology
The cysteine hydrochloride weighing recipe quantity is dissolved in appropriate water for injection, stirring and dissolving, adds depending on of recipe quantity
Da Lafeng, stirring and dissolving, regulate pH value by pH value regulator, add methyl hydroxybenzoate and the sodium chloride of recipe quantity, stirring and dissolving, then
Secondary pH value regulator regulates pH value, and pH value regulation is complete, is settled to total amount, stirring and evenly mixing with water for injection, filters, fill,
Sterilizing, visual inspection gets product.
Comparative example 2:
Prescription
Preparation technology
The cysteine hydrochloride and the disodium glycyrrhizinate that weigh recipe quantity are dissolved in appropriate water for injection, and stirring and dissolving adds
Enter the Edaravone of recipe quantity, stirring and dissolving, regulate pH value by pH value regulator, add the sodium chloride of recipe quantity, stirring and dissolving,
Again regulating pH value by pH value regulator, pH value regulation is complete, is settled to total amount, stirring and evenly mixing with water for injection, filters, fills
Dress, sterilizing, visual inspection gets product.
Comparative example 3:
Prescription
Preparation technology
The cysteine hydrochloride and the disodium glycyrrhizinate that weigh recipe quantity are dissolved in appropriate water for injection, and stirring and dissolving adds
Enter the Edaravone of recipe quantity, stirring and dissolving, regulate pH value by pH value regulator, add methyl hydroxybenzoate and the chlorination of recipe quantity
Sodium, stirring and dissolving, again regulate pH value by pH value regulator, pH value regulation is complete, is settled to total amount with water for injection, and stirring is mixed
Even, to filter, fill, sterilizing, visual inspection gets product.
Comparative example 4:
Prescription
Preparation technology
The cysteine hydrochloride and the sodium sulfite that weigh recipe quantity are dissolved in appropriate water for injection, and stirring and dissolving adds
Enter the Edaravone of recipe quantity, stirring and dissolving, regulate pH value by pH value regulator, add the sodium chloride of recipe quantity, stirring and dissolving,
Again regulating pH value by pH value regulator, pH value regulation is complete, is settled to total amount, stirring and evenly mixing with water for injection, filters, fills
Dress, sterilizing, visual inspection gets product.
Comparative example 5:
Prescription
Preparation technology
Weighing the 1,2-PD of recipe quantity and ethanol joins full dose 30% water for injection of 50～60 DEG C, stirring is mixed
Even, Edaravone and the sodium pyrosulfite of recipe quantity are added to above-mentioned solution, after stirring, quantitative with water for injection
To full dose, adjusting pH value to 4.5～5.5 with hydrochloric acid, filter, fill, sterilizing, visual inspection gets product.
Comparative example 6:
Prescription
Preparation technology
Weighing the Edaravone of recipe quantity, the water for injection of 90～100 DEG C of addition 1/2～1/3 recipe quantity, stirring is completely
Dissolve, obtain Edaravone solution；Weigh the vitamin C of recipe quantity, glutathion joins above-mentioned solution, stirs, adds
Water for injection, to the 80% of recipe quantity, is cooled to 70-80 DEG C, obtains mixed solution；Doctor is added in described mixed solution
With activated carbon, the addition of described medical activated carbon is that 0.3% (W/V) stirs 15 minutes, carries out filtration treatment while hot and makes above-mentioned
Mixed solution takes off charcoal, obtains filtrate；Add to the full amount of water for injection in described filtrate, then with 1M dilute hydrochloric acid or 1M sodium hydroxide
Test solution regulation pH value is 4.0～4.5, is uniformly mixed, filters, and fill, sterilizing, visual inspection gets product.
Checking embodiment
1. product yield contrast
The embodiment of the present invention 1～5 is collected with comparative example 1～6 gained finished product preparation final amt, its yield
The results are shown in Table 1
Table 1 embodiment 1～5 contrasts with comparative example 1～4 preparation yield
From experiment investigation result: embodiment of the present invention yield comparative example to be substantially better than 1,2,4,5,6, simultaneously
It has also been discovered that, the regulation of pH value does not affect for its yield.
2. long term test
Embodiment 1～5 and contrast are implemented the preparation obtained by 3 put into 25 DEG C, in RH60% climatic chamber, respectively at
0,6, December sampling, investigate its appearance character, it is seen that foreign body, pH, have the situation of change of related substance and content, the results are shown in Table 2.
Table 2 embodiment 1～5 and contrast are implemented 3 preparation long term tests and are investigated result
From experiment investigation result: preparation indices obtained by the embodiment of the present invention 1～5 all meets regulation, and right
Than preparation obtained by embodiment 3 along with standing time prolongation its have related substance to become big, its content reduces, and considers, this
Bright yield is high, and safety is good, steady quality, prepares and promotes aborning.
Claims (10)
1. treat the injection of disturbance of consciousness after cerebral trauma and brain surgery for one kind, it is characterised in that described injection is become by activity
Divide Edaravone, sodium chloride, cysteine hydrochloride, disodium glycyrrhizinate, methyl hydroxybenzoate, pH adjusting agent and water for injection composition.
The injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 1 and brain surgery, it is characterised in that described
Active component Edaravone concentration be 1.0～4.0mg/ml.
The injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 1 and brain surgery, it is characterised in that described
CYSTEAMINE HCL acid concentration be 0.2～0.4mg/ml.
The injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 1 and brain surgery, it is characterised in that described
Disodium glycyrrhizinate concentration be 0.8～1.2mg/ml.
The injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 1 and brain surgery, it is characterised in that described
Methyl hydroxybenzoate concentration be 0.1～0.3mg/ml.
The injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 1 and brain surgery, it is characterised in that described
Active component Edaravone concentration be 1.5mg/ml, described CYSTEAMINE HCL acid concentration is 0.3mg/ml, described Radix Glycyrrhizae
Acid disodium concentration is 1.0mg/ml, and described methyl hydroxybenzoate concentration is 0.2mg/ml.
The injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 1 and brain surgery, it is characterised in that described
PH adjusting agent be the one in sodium hydroxide, sodium phosphate, sodium acetate and sodium citrate or several, pH scope be 4.6～
5.2。
The injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 1 and brain surgery, it is characterised in that described
Injection be sodium hydroxide, pH is 4.9.
9. according to the injection of disturbance of consciousness after the treatment cerebral trauma described in any claim in claim 1-8 and brain surgery
Preparation method, it is characterised in that comprise the following steps: the cysteine hydrochloride and the disodium glycyrrhizinate that weigh recipe quantity are dissolved in 70
～90% water for injection in, stirring and dissolving, add recipe quantity Edaravone, stirring and dissolving, regulate pH by pH value regulator
Value, pH value regulation is complete, adds methyl hydroxybenzoate and sodium chloride, the stirring and dissolving of recipe quantity, again regulates pH by pH value regulator
Value, pH value regulation is complete, is settled to total amount, stirring and evenly mixing with water for injection, filters, and fill, sterilizing, visual inspection gets product.
The preparation method of the injection of disturbance of consciousness after treatment cerebral trauma the most according to claim 9 and brain surgery, it is special
Levy and be, its preparation method more preferably following steps: the cysteine hydrochloride and the disodium glycyrrhizinate that weigh recipe quantity are molten
In the water for injection of 80%, stirring and dissolving, add the Edaravone of recipe quantity, stirring and dissolving, by the hydroxide of 0.1mol/L
Sodium solution regulation pH value, pH value regulation is complete, adds methyl hydroxybenzoate and sodium chloride, the stirring and dissolving of recipe quantity, again uses
The sodium hydroxide solution regulation pH value of 0.1mol/L, pH value regulation is complete, is settled to total amount, stirring and evenly mixing, mistake with water for injection
Filter, fill, sterilizing, visual inspection gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610430919.3A CN106074366B (en) | 2016-06-16 | 2016-06-16 | The injection and preparation method thereof for treating the disturbance of consciousness after brain trauma and brain surgery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610430919.3A CN106074366B (en) | 2016-06-16 | 2016-06-16 | The injection and preparation method thereof for treating the disturbance of consciousness after brain trauma and brain surgery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106074366A true CN106074366A (en) | 2016-11-09 |
| CN106074366B CN106074366B (en) | 2018-11-23 |
Family
ID=57236098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610430919.3A Expired - Fee Related CN106074366B (en) | 2016-06-16 | 2016-06-16 | The injection and preparation method thereof for treating the disturbance of consciousness after brain trauma and brain surgery |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074366B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115177585A (en) * | 2022-07-29 | 2022-10-14 | 浙江普利药业有限公司 | Nimodipine oral solution and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040147606A1 (en) * | 2001-05-25 | 2004-07-29 | Yoichi Onuki | Medicinal compositions |
| CN104784111A (en) * | 2015-03-28 | 2015-07-22 | 河北仁合益康药业有限公司 | Edaravone injection composition and preparation method thereof |
-
2016
- 2016-06-16 CN CN201610430919.3A patent/CN106074366B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040147606A1 (en) * | 2001-05-25 | 2004-07-29 | Yoichi Onuki | Medicinal compositions |
| CN104784111A (en) * | 2015-03-28 | 2015-07-22 | 河北仁合益康药业有限公司 | Edaravone injection composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 郭涛，等: "依达拉奉氯化钠注射液的制备和稳定性考察", 《沈阳部队医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115177585A (en) * | 2022-07-29 | 2022-10-14 | 浙江普利药业有限公司 | Nimodipine oral solution and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106074366B (en) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020073559A1 (en) | Flurbiprofen axetil emulsion for injection and preparation method therefor | |
| CN107823128B (en) | A kind of preparation method of Edaravone Injection | |
| CN107823149A (en) | A kind of injection Angiomax and preparation method thereof | |
| CN102579329A (en) | Milrinone lactate injection and preparation method thereof | |
| JP2018501291A (en) | Sulfonamide pharmaceutical composition | |
| US11975099B2 (en) | Ethanol foam sclerosing agent for treating vascular anomalies and preparation method thereof | |
| CN104706655B (en) | Meglumine cyclic adenosine for injecta powder-injection pharmaceutical composition and preparation method | |
| CN106074366A (en) | Injection of disturbance of consciousness and preparation method thereof after treatment cerebral trauma and brain surgery | |
| CN104069063B (en) | Fasudic hydrochloride pharmaceutical composition and preparation method thereof | |
| CN109758423A (en) | Use the method for vitamin K1 fat emulsion injection treatment coagulation disorders | |
| CN108324683A (en) | A kind of big infusion Edaravone Injection and its preparation process of stabilization | |
| US2530480A (en) | Therapeutic preparations for intramuscular and subcutaneous injection and methods of making the same | |
| CN104922661B (en) | A kind of pharmaceutical composition and preparation method thereof containing serelaxin | |
| CN109528632A (en) | Nimodipine pharmaceutical composition, nimotop vial and preparation method thereof | |
| CN103202805B (en) | Vinpocetine-containing pharmaceutical composition for injection and preparation method thereof | |
| CN105832664A (en) | Isosorbide dinitrate injection and preparation method thereof | |
| CN108210879A (en) | A kind of pharmaceutical composition for treating acute Cerebral bleeding and its application | |
| CN105935443A (en) | Pharmaceutical composition for treating diabetic cataract | |
| CN109806226A (en) | The purposes of vitamin K1 fat emulsion injection | |
| CN102526112B (en) | Sustained-release pearl clear-sighted eye drops and preparation method thereof | |
| CN102772373B (en) | A kind of injection vinorelbine tartrate injectable powder and preparation method thereof | |
| CN105769776B (en) | A kind of freeze-dried composition for treating non-Hodgkin lymphoma and preparation method thereof | |
| CN115154423B (en) | Ibandronate sodium injection and preparation method thereof | |
| CN109806225B (en) | Vitamin K1 fat emulsion injection | |
| CN103784397B (en) | Puerarin sodium phosphate injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181123 Termination date: 20200616 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |